Horama Joins Race To Develop Gene Therapies For Eye Diseases
Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.
You may also be interested in...
An early-stage, small-molecule approach to the treatment of retinitis pigmentosa being developed by US biotech OptiKira may have potential benefits over more advanced gene and cell therapies for the blindness-causing condition.
Philadelphia-based Spark Therapeutics has acquired private, Irish gene therapy company, Genable Technologies, for $6m in cash and 265,000 shares of Spark common stock.
In yet another deal, Roche is acquiring rare disease drug developer Trophos at a price of €120m upfront, and a further €350m in potential milestone payments.